Letter From The Editor

When we publish clinical information most of the time it is a study where the parameters are closely controlled. This means that often the human factor is not included in the results. These human factors could be as simple as missing a dose, but even more likely these problems are …

Over the past year we have provided you with over 850 articles, interviews, best products, snippets of knowledge, tests of knowledge, and educational videos. Each and every week our staff looks over the latest and greatest in diabetes care, and we select what we think you will be most interested …

Happy Holidays from all of us here at Diabetes In Control. Dr. Jeffrey Mechanick, from the  Icahn School of Medicine at Mount Sinai, NY, was chosen president of the American College of Endocrinology this past year and played a big role in new Joint A1c recommendations. He has been chatting …

When we began 2016, we were just starting to see the value of the SGLT-2 Inhibitors gain momentum. In fact, our first feature of the year looked at mixing an SGLT-2 Inhibitor with a DPP-4i and Metformin to maximize glucose control, and over the year we reviewed over 40 articles and …

When you think of the holidays, everyone’s mind often drifts to gifts, whether it is a husband thinking what to get his wife or a child thinking about a new game they have to have. Regardless of whether you are are on the giving or receiving side, it would be …

Recently the ADA and the AHA came together to adjust the guidelines in diabetes patients with cardiovascular problems. They have agreed that managing the cardiovascular problems should be the guiding light in overall patient care, and worrying about A1c levels is of less importance. This is especially true in older patients. …

A few years ago Dr. Steven Nissen turned the diabetes world upside down when he went on a crusade to get TZD’s off the market due to cardiovascular risk. One of the results of his efforts was the FDA’s requirement that all new diabetes drugs would have extensive cardiovascular testing, …

Over the years Steve and I have reviewed many PowerPoint presentations on diabetes, and we have published quite a few of these ourselves. Whenever the presentation explained how type 2 diabetes developed, there was always a slide showing increased insulin resistance and decreased insulin production. Wherever these 2 lines crossed, …

It has been 10 years since Sitagliptin was approved by the FDA. When it was first approved there was a lot of pushback from prescribers to trying a new class, as the last class, the TZDs, had suffered through the problems with Rezulin and the cardiovascular problems associated with Actos …

As we approach the holiday season a lot of patients will bring you gifts, and many of them will be handmade creations, including some of the gaudiest sweaters known to mankind. Some people are good enough to design these creations as they go along, but most people have to use …